Changes in antimicrobial resistance of Escherichia coli causing urinary tract infections in hospitalized children by Fritzsche, M. et al.
Eur J Clin Microbiol Infect Dis (2005) 24: 233–235
DOI 10.1007/s10096-005-1301-2
BRIEF REPORT
M. Fritzsche · R. A. Ammann · S. Droz ·
M. G. Bianchetti · C. Aebi
Changes in antimicrobial resistance of Escherichia coli causing
urinary tract infections in hospitalized children
Published online: 17 March 2005
C© Springer-Verlag 2005
Urinary tract infections (UTI) are among the most common
bacterial infections of childhood. Rapid recognition and
appropriate antimicrobial therapy relieve symptoms and
prevent renal damage [1]. Since therapy for suspected UTI
is usually initiated before the responsible organism and its
susceptibility to antimicrobial agents are known, the ra-
tional choice of an antibiotic relies on local epidemiologic
data. In infants and young children without a known urinary
tract malformation, Escherichia coli is responsible for the
vast majority of episodes [2, 3]. Recent studies suggest that
in these patients intravenous antibiotic therapy for acute
pyelonephritis may no longer be warranted, and that most
patients can be treated safely with oral third-generation
cephalosporins [3, 4]. However, since outpatient oral
therapy for acute pyelonephritis requires certainty that
the drug used is active against the expected pathogens,
this trend is somewhat at odds with the increasing antimi-
crobial resistance detected among isolates of Escherichia
coli in recent years [5–7]. The aim of the retrospective
study reported here was to investigate changes in the
antimicrobial resistance of Escherichia coli causing acute
pyelonephritis in children hospitalized with a UTI during
2 decades.
Two study periods were chosen for investigation. The
first period from 1980 to 1991 was based on reference
data provided by a previous study conducted by one of the
present authors (M.G.B.) at the same study site [8]. A power
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analysis based on this study’s data gave us a comparator
group size of 150 patients to detect a 10% difference in
resistance to amoxicillin-clavulanate (power, 80%; α level,
5%) between the Escherichia coli isolates examined in the
first period [8] compared with those obtained during a sec-
ond, more recent, study period. Thus, the duration of the
second study period was set to allow for the inclusion of
150 patients <16 years of age who were diagnosed and
hospitalized most recently with their first UTI. The dura-
tion of this period consequently extended from 1 January
2000 to 31 December 2003.
Inclusion criteria were identical in both periods and con-
sisted of (i) significant Escherichia coli bacteriuria, defined
as ≥105 colony forming units/ml of bag-collected or mid-
stream urine or ≥104 colony forming units/ml of urine
obtained by transurethral catheterization, and (ii) severe
or moderate UTI defined by clinical criteria. Severe UTI
was recorded if at least one of the following four criteria
were present: (i) Escherichia coli bacteremia, (ii) urinary
leukocyte casts, (iii) sonography findings characteristic for
pyelonephritis, (iv) serum creatinine >50 µmol/l above the
age-related upper limit of the normal range. Moderate UTI
required at least three of the following criteria for diag-
nosis: (i) age <1 year, (ii) costovertebral angle tender-
ness, (iii) C-reactive protein >30 mg/l or erythrocyte sedi-
mentation rate >30 mm/h, (iv) peripheral leukocyte count
>15.0×109/l, (v) left-shift with >12% band forms. Ex-
clusion criteria included a history of previous UTI, known
urinary tract malformation, neurogenic bladder dysfunc-
tion, renoparenchymal disorders, immunodeficiency or re-
cent transurethral catheterization prior to that used in the
present episode.
Urine specimens were transported to the laboratory using
BD Vacutainer tubes (BD Vacutainer, C&S Kit, Franklin
Lakes, NJ, USA). Standard techniques were used for cul-
ture and identification of Escherichia coli. Susceptibility
testing was performed using the disk diffusion technique
according to the guidelines of the National Committee of
Clinical Laboratory Standards. Organisms with intermedi-
ate susceptibility were considered sensitive. Comparisons
between the study periods were made using the two-tailed
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Table 1 Comparison of antimicrobial resistance in Escherichia coli
isolates obtained from Swiss children hospitalized with acute urinary
tract infection during two study periods
Antimicrobial agent No. (%) of resistant isolates p value
1980–1991 [8]
(n=203)
2000–2003
(n=151)
Ampicillin 67 (33) 78 (51) <0.001
Amoxicillin-clavulanate 30 (17) 17 (11) 0.16
Cotrimoxazole 32 (16) 38 (25) 0.031
Cephalothin nt 25 (17) –
Cefuroxime nt 2 (1.3) –
Cefuroxime-axetil nt 2 (1.3) –
Ceftriaxone nt 0 (0) –
nt, not tested
Fisher exact test. Statistical significance was defined as a p
value of <0.05.
In the first (1980–1991) [8] and second (2000–2003)
study periods, 203 and 151 patients, respectively, were
compared. There were no statistically significant differ-
ences in age (median age, 6 months [range, 1 week–15
years] vs. 11 months [1 week–12 years]), gender (female,
53% vs. 66%), and proportion of severe vs. moderate UTI
(36% vs. 28%) between the first and second study periods,
respectively. More detailed data on urinary findings were
available for cases in the second study period as follows.
Ninety (60%) patients had specimens collected by bag,
36 (24%) by catheterization, and 25 (17%) by mid-stream
voiding collection. In 25 (17%) specimens, a second bac-
terial pathogen was isolated. Thirteen (9%) patients had
been treated with an oral antibiotic at the time of hospital
admission.
Table 1 lists the rates of Escherichia coli resistance found
during both study periods. Resistance to ampicillin and
cotrimoxazole increased significantly. The decrease in re-
sistance to amoxicillin-clavulanate was not significant. Of
the 38 strains that demonstrated resistance to cotrimoxa-
zole in the second study period, 36 (95%), 12 (32%), and
11 (29%) were also resistant to ampicillin, amoxicillin-
clavulanate, and cephalothin, respectively. Forty-seven
(31%) isolates were resistant to at least two of the
antibiotics tested, and 19 (13%) were resistant to at
least three agents.
In comparison with previous reports [5–6], this study
covers an extended observation period and care was
taken to ensure that Escherichia coli isolates originated
from patients with comparable clinical disease, i.e.,
community-acquired UTI with a high likelihood of
renal involvement in previously healthy children. Since
standard management of febrile UTI in Switzerland entails
hospitalization, our findings are representative of all
febrile UTI episodes occurring in this study area during the
two study periods.
Previous studies have mostly reported susceptibility data
without considering clinical data in detail. Our major find-
ings are consistent with those of recent pediatric studies
from the UK [5], Israel [6], and Germany [7], and they
demonstrate a statistically significant increase in resistance
to ampicillin and cotrimoxazole over 2 decades but mainte-
nance of full susceptibility to second- and third-generation
cephalosporins. While few data from Switzerland are avail-
able for comparison, one hospital-based study from Zurich
showed lower rates of ampicillin resistance (44%) but
higher rates of amoxicillin-clavulanate (33%) and cotri-
moxazole (42%) resistance in children [9]. Among UTI iso-
lates from Swiss women in 2000 substantially lower rates
of resistance were detected (ampicillin, 27%; amoxicillin-
clavulanate, 2.5%; cotrimoxazole, 19%) [10]. The truly
unexpected finding in our study was the decrease in re-
sistance to amoxicillin-clavulanate, since resistance rates
are known to be influenced by local preferences in the
use of antibiotics [11] and sales of pediatric formulations
of amoxicillin-clavulanate in Switzerland have continu-
ously risen over the past decade. Thus, one would ex-
pect an increase in selective pressure as a growing pro-
portion of UTI patients have been previously exposed
to this antibiotic.
Our findings have a direct impact on the choice of an an-
timicrobial agent for the empiric treatment of pediatric UTI
in Switzerland. Amoxicillin should no longer be used. In
a child with cystitis (i.e., who is afebrile and has a normal
C-reactive protein level), amoxicillin-clavulanate and cot-
rimoxazole can still be used for first-line therapy. However,
physicians electing to treat febrile UTI orally should use a
second- or third-generation cephalosporin in order to avoid
treatment failure caused by antimicrobial resistance. Using
ceftriaxone as a marker, third-generation cephalosporins
were found to be fully susceptible (Table 1), and compar-
ative clinical studies have documented their efficacy in the
oral therapy of infants and children with acute pyelonephri-
tis [2, 3].
It is possible that our data overestimate the overall rates of
resistance in the community for a number of reasons. First,
our analysis of hospitalized children may be biased towards
higher rates of resistance compared with those found for
patients treated in an outpatient setting, even though only
9% of our patients had received oral antibiotic therapy at
the time of hospital admission. Second, urinary pathogens
causing mild UTI, which were excluded from our study,
may show lower rates of resistance. Antimicrobial resis-
tance in the group of patients with moderate UTI, however,
was not significantly different from that in the group with
severe UTI (data not shown). Third, the impact of in vitro
resistance on clinical outcome is not clear. Since drugs such
as β-lactam agents and cotrimoxazole reach high urinary
concentrations for prolonged periods of time, it is possible
that in vitro findings do not accurately predict treatment
failure. However, existing data for UTI in adults suggest
that infection with resistant organisms may adversely af-
fect clinical outcome [12].
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